A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN - Melichar, Bohuslav; Mickisch, Gerald (Annals of oncology, 2013)
Gesehen am: 18.03.2015